VELCADE®(For medical professional reference only)
Trade name
VELCADE®(For medical professional reference only)
Generic name
Bortezomib for injection
Appearance
This product is white or off-white lump or powder.
Indication
•Multiple Myeloma(MM)
VELCADE, in combination with melphalan and prednisone (MP regimen) is indicated for treatment-naive patients with multiple myeloma who are not candidates for high dose chemotherapy and bone marrow transplantation. Velcade can be also used alone for patients with relapsed multiple myeloma after receiving at least one or more than one therapy.
•Mantle Cell Lymphoma(MCL)
The product is indicated for patients with relapsed or refractory MCL. The patient should have received at least one type of therapy before. Safety and efficacy data for this indication comes from a single-arm, phase II study conducted out of China in patients with relapsed MCL after treatment (see [Clinical Trials]). Data from clinical studies of Chinese population are not available at present.
Indication
<div>•Multiple Myeloma(MM)</div><p>VELCADE, in combination with melphalan and prednisone (MP regimen) is indicated for treatment-naive patients with multiple myeloma who are not candidates for high dose chemotherapy and bone marrow transplantation. Velcade can be also used alone for patients with relapsed multiple myeloma after receiving at least one or more than one therapy.</p><div>•Mantle Cell Lymphoma(MCL)</div><p> The product is indicated for patients with relapsed or refractory MCL. The patient should have received at least one type of therapy before. Safety and efficacy data for this indication comes from a single-arm, phase II study conducted out of China in patients with relapsed MCL after treatment (see [Clinical Trials]). Data from clinical studies of Chinese population are not available at present. </p>